SK Biopharma’s CEO, Donghoon Lee, announced a strategic shift towards open innovation and artificial intelligence as key drivers for new drug development. Speaking in San Diego, Lee emphasized these approaches as solutions to accelerate the pharmaceutical innovation process. The company intends to actively pursue collaborations and leverage AI technologies to enhance research and development capabilities. This move signals a commitment to adapting to the evolving landscape of the pharmaceutical industry, where speed and efficiency are paramount. SK Biopharma aims to overcome traditional drug development hurdles through these innovative strategies. The focus on AI and open innovation is expected to streamline the identification of promising drug candidates and expedite clinical trials. This represents a significant investment in future growth and competitiveness for the company.